Medtronic PLC Company Profile (NYSE:MDT)

Medtronic PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

Medtronic PLC declared a quarterly dividend on Monday, August 28th. Investors of record on Friday, September 29th will be paid a dividend of $0.46 per share on Friday, October 20th. This represents a $1.84 annualized dividend and a dividend yield of 2.36%. The ex-dividend date of this dividend is Thursday, September 28th. View Medtronic PLC's Dividend History.

Medtronic PLC declared that its board has authorized a stock repurchase plan on Thursday, October 5th 2017, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 49% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's board of directors believes its stock is undervalued.

Medtronic PLC (NYSE:MDT) released its earnings results on Tuesday, August, 22nd. The company reported $1.12 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.08 by $0.04. The firm had revenue of $7.39 billion for the quarter, compared to analyst estimates of $7.44 billion. Medtronic PLC had a return on equity of 12.92% and a net margin of 13.75%. Medtronic PLC's quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the company posted $1.03 EPS. View Medtronic PLC's Earnings History.

Medtronic PLC is scheduled to release their next quarterly earnings announcement on Tuesday, November, 28th 2017. View Earnings Estimates for Medtronic PLC.

22 analysts have issued 1-year target prices for Medtronic PLC's shares. Their predictions range from $78.00 to $96.00. On average, they expect Medtronic PLC's share price to reach $88.00 in the next twelve months. View Analyst Ratings for Medtronic PLC.

Here are some recent quotes from research analysts about Medtronic PLC stock:

• 1. According to Zacks Investment Research, "Over the last three months, Medtronic has been observed to underperform the broader industry. We note that, escalating costs and expenses are weighing on margins. Also, unfavorable foreign exchange continues to remain a drag. On a positive note,  we observe that apart from displaying successful integration and achievement of synergy targets, Medtronic’s major business groups continue to contribute to top-line growth which highlighted sustainability across all segments and geographies. Recently, the company announced the receipt of regulatory approval from the Japanese MHLW for its IN.PACT Admiral Drug-Coated Balloon. The stabilizing trend in the global Cardiac Rhythm & Heart Failure (CRHF) market is another upside. We are also encouraged by the solid growth trend, continuing in the U.S. as well as the healthy global acceptance of its advanced therapies." (9/12/2017)
• 2. Needham & Company LLC analysts commented, "F4Q17 revenue and EPS beat consensus and initial FY18 guidance was in line with consensus. Organic revenue growth was steady at 4.0% vs. 4.1% in F3Q17 with new products adding ~370 bps, emerging markets adding ~125 bps and services & solutions adding ~15 bps. Operating margin was above consensus and up 10 bps Y/Y (or 40 bps Y/Y CC). MDT’s product cycle remains strong with significant FY18 launches including: the Resolute Onyx DES, MiniMed 670G insulin pump, Signia powered stapler, new LigaSure instruments, Intellis spinal cord stimulator, Evolut PRO TAVR, and MRI CRT-P quadripolar system." (5/25/2017)
• 3. BTIG Research analysts commented, "At last Friday's American College of Cardiology (ACC) meeting, two-year data on MDT's SURTAVI trial for intermediate-risk was presented. At the two-year mark, all cause death/stroke were similar for TAVR using MDT's valves (12.6%) vs. surgery (14%) though use of TAVR reduced 30-day strokes, kidney injury, afib, and hospital stay. While we were surprised TAVR was not superior to surgery as in other trials, it seems surgical results improved. Still, TAVR is at least as good with less invasiveness. While not the same trials, investors have tried to compare MDT's CoreValve to Edwards' (EW, Neutral) SAPIEN 3 based on available data. At 1 year, all-cause death and stroke were equivalent at 8.1% for CoreValve and 8.4% for SAPIEN 3. Overall, patient selection (EW's intermediate risk pool may have had more comorbidities) and device design (MDT mainly used its older valve) make it tough to directly compare both trials; but we believe the valves are essentially equivalent and either one should be chosen over surgery." (3/20/2017)
• 4. Wedbush analysts commented, "Medtronic's broad product portfolio allows the company to navigate through temporary disruptions it might encounter in any given business unit, and today's FY3Q17 earnings results showcased management's ability to leverage its size and recover more quickly than we had expected from its disappointing FY2Q17 performance reported in November. With MDT's share price having mostly recovered from the post FY2Q17 selloff, we believe current valuation levels adequately reflect MDT's risk/reward profile and prefer to wait on the sidelines for a better entry point. ' FY3Q17 revenue of $7,283 million (+6% yr/yr, ex-FX) beat consensus revenue estimate of $7,220 million. Revenue from all four segments exceeded consensus, with the biggest contribution from Minimally Invasive Therapies Group (MTIG) and Diabetes' Our $85 PT is based on applying a 16x P/E multiple on our MDT forward EPS estimate, 12 months hence." (2/22/2017)
• 5. Evercore ISI analysts commented, "MDT started 2017 with a solid execution, highlighted by all around revenue beat and operating margins that were generally in line with ST (came in above us). The importance of this Q cannot be underestimated in our mind, as sentiment had turned negative (post a disappointing 1H) and the stock multiple (3-6x discount to peer group) was see-sawing precariously at ~15-16x P/E. While the bar had been lowered, MDT needed to deliver to flawless Q to instill investor confidence and start the path towards multiple correction (vs. group). The company began its first step, highlighted by a solid revenue beat, driven by high single digit growth in CR&HF. This is a key segment, and the ~8% growth should provide comfort against the bear thesis of competitive share losses / replacement cycle headwinds. We were also encouraged to see ~30% growth in TAVR, and a full rollout of the 34mm valve (launched only in 50% of centers) plus Intermediate Risk approval in early 2018 bodes well. Other key drivers in 2018 include the full commercial launch of 670G in Diabetes, Resolute Onyx launch, continued growth in AF, Link, DCBs, and the continued turnaround in Spine provides incremental confidence in MDT being able to sustain ~4% organic topline in the medium term. The second leg of value creation will rest on margin expansion, with the ST still skeptical of the company's ability to show margin expansion on a reported basis (including the impact of Fx hedges). We believe that the margin expansion thesis will play out in 2018, and will play a huge role in MDT's ability to close its P/E gap vs. peer group average. We expect this combination of a potential multiple reflation trade along with upside from capital deployment (incremental ~$3 Bn could potentially be accessible in near term post IRS settlement) to drive value for investors over the next 12 months." (2/21/2017)

Medtronic PLC saw a increase in short interest during the month of September. As of September 29th, there was short interest totalling 11,531,235 shares, an increase of 28.7% from the September 15th total of 8,960,370 shares. Based on an average trading volume of 5,401,377 shares, the days-to-cover ratio is currently 2.1 days. Approximately 0.9% of the shares of the stock are sold short.

Some companies that are related to Medtronic PLC include Novartis AG (NVS), UnitedHealth Group Incorporated (UNH), Merck & Company (MRK), AbbVie (ABBV), Amgen (AMGN), Sanofi (SNY), Novo Nordisk A/S (NVO), Celgene Corporation (CELG), Bristol-Myers Squibb Company (BMY), Gilead Sciences (GILD), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), Thermo Fisher Scientific (TMO), Biogen (BIIB), Allergan PLC. (AGN) and Stryker Corporation (SYK).

Medtronic PLC's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Park National Corp OH (0.01%) and Osborn Williams & Donohoe LLC (0.00%). Company insiders that own Medtronic PLC stock include Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Kendall J Powell, Omar Ishrak, Richard H Anderson, Richard Kuntz, Robert C Pozen and Shirley A Jackson. View Institutional Ownership Trends for Medtronic PLC.

Medtronic PLC's stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH and Osborn Williams & Donohoe LLC. Company insiders that have sold Medtronic PLC stock in the last year include Bryan C Hanson, Hoedt Rob Ten, Hooman Hakami and Omar Ishrak. View Insider Buying and Selling for Medtronic PLC.

Shares of Medtronic PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Medtronic PLC stock can currently be purchased for approximately $78.00.